At Dennis Partners, we know regulatory recruiting. We are committed to creating and maintaining partnerships with our clients while upholding the highest standards of professionalism and ethics. Our team interacts within the marketplace on a daily basis, giving us the ability to locate, screen, and recommend exceptional individuals to your firm. We know how to identify the top performers. Our strength is partnering with you and your business to develop a solution and meet demands for growth while improving efficiency. Let our advanced expertise find the top professionals in the industry to provide a competitive edge to your company.
We have your specialization covered
Contract-to-hire evaluation process
We're on your side
Complete back office support
Our process is cost-effective
Dennis Partner’s focus on only regulatory affairs searches gives them a very good sense of the market, the available talent, and who matches the role. They worked with us diligently to find the right candidate and we ended up making an exceptional hire.
We take the time to evaluate your needs beyond a job description
We identify top talent from our research and competitive analysis
We analyze the talent to match candidates on a deeper level
We go beyond the hire by offering extensive post placement services
Does your company have immediate top-tier talent needs?
Meet Our Team
The FDA gave the green light to Boston Scientific’s first-of-its-kind electric pulse system designed to treat pain without the use of opioids. https://www.fiercebiotech.com/medtech/fda-clears-boston-scientific-s-electric-pulse-system-for-non-opioid-pain-management Roche said that the EU approved Ocrevus for relapsing forms of multiple sclerosis and primary progressive multiple sclerosis, a form of the neurological disease that previously was without an approved medicine. https://www.reuters.com/article/us-roche-ocrevus/roches-star-ms-medicine-ocrevus-wins-eu-approval-idUSKBN1F10JN[…]
A recurring topic that I discuss with candidates on a daily basis is the pros and cons of making a planned strategic career move. Will this hinder or help their career in the long run? There is a big difference between being a “job hopper” and making strategic career moves. A “job hopper” has made[…]
Happy New Year and I hope you all enjoyed the holidays. Here is my recap of the top regulatory news stories for this week, along with a few notable things that happened during the holiday break… U.S. drug approvals hit a 21-year high in 2017, with 46 novel medicines winning a green light — more than[…]
This has been a big week with the approval of three new molecular entities by the FDA and the first gene therapy approved for a genetic disease. Here are the top regulatory news stores for the week. Please note that this will be my last blog of 2017 and I will be back the first[…]
Hi folks. Here are the top regulatory news stories for this week: Pfizer Inc. announced today that the FDA has approved IXIFI™ a chimeric human-murine monoclonal antibody (mAb) against tumor necrosis factor, as a biosimilar to Remicade® (infliximab) for all eligible indications of the reference product. https://www.firstwordpharma.com/node/1529996#axzz51FIjJ9GS The FDA approved Sanofi’s rapid-acting insulin analog Admelog[…]
I am posting my regulatory news blog early since I will be out of the office tomorrow. Here are the top regulatory news stories this week: The U.S. FDA approved Mylan’s biosimilar of Roche’s blockbuster treatment for breast cancer, Herceptin. This is the eighth biosimilar to be approved by the FDA: https://www.reuters.com/article/us-mylan-nl-fda/fda-oks-mylans-biosimilar-of-roche-cancer-drug-herceptin-idUSKBN1DV5BI Sunovion received FDA[…]
Hi folks, I’m publishing my blog a day early since I will be out of the office tomorrow. Here are the top regulatory news stories for this week: Scott Gottlieb, the commissioner of the Food and Drug Administration, announced plans to speed generic versions of treatments that combine a drug and a device: https://www.forbes.com/sites/matthewherper/2017/11/28/fda-boss-aims-to-close-epipen-loophole/#4af7e7fe39f9 According[…]
This has been a big week with multiple approvals by the FDA for new molecular entities along with the approval of the first digital pill and a couple of supplemental approvals. Here is my summary of the top regulatory news stories for pharma and biotech this week: Ultragenyx announced that the FDA has approved MEPSEVII™[…]
Hi folks. I am posting a day early since I will be out of the office tomorrow. The big news this week was the approval of a new molecular entity for Merck along with new indication approvals for both Genentech and Keryx. Here is my summary of the top stories this week: Merck announced that[…]
This week saw the approval of two new molecular entities by the FDA along with a strong advisory panel recommendation. Here is my recap of the top regulatory news stories to follow: Valeant Pharmaceuticals has won U.S. FDA approval for its glaucoma drug Vyzulta ending a more than two-year effort to bring the drug to[…]